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Musical hallucinations are relatively rare auditory percepts which, due to their intrusive
nature and the accompanying fear of impending mental decline, tend to cause significant
distress and impairment. Although their etiology and pathophysiology appear to be hetero-
geneous and no evidence-based treatment methods are available, case reports indicate that
acetylcholinesterase inhibitors may yield positive results in patients with comorbid hear-
ing loss. We present two female patients (aged 76 and 78 years) both of whom suffered
from hearing impairment and practically incessant musical hallucinations. Both patients
were successfully treated with the acetylcholinesterase inhibitor rivastigmine. Based on
these two case descriptions and an overview of studies describing the use of acetyl-
cholinesterase inhibitors in similar patients, we discuss possible mechanisms and propose
further research on the use of acetylcholinesterase inhibitors for musical hallucinations
experienced in concordance with hearing loss.
Keywords: auditory Charles Bonnet syndrome, cholinergic system, deafferentiation, donepezil, hearing loss, Oliver
Sacks’ syndrome, release hallucination, rivastigmine
INTRODUCTION
Musical hallucinations (also known as musical hallucinosis, audi-
tory Charles Bonnet syndrome, and Oliver Sacks’ syndrome) are
characterized by hallucinated songs, tunes, melodies, harmonics,
rhythms, and/or timbres (1). They can be perceived within the
head, or as though emanating from the environment. However, by
definition, they are perceptual in nature and thus different from
the “earworms” or “tunes in the head” that we all experience at
times (2). When first perceiving musical hallucinations, people
tend to attribute them to an external source but, within a few days,
most realize that the music originates from “within” their head.
Insight is often intact and, apart from hearing loss or tinnitus,
most patients display no additional comorbidity. Therefore, the
term “idiopathic musical hallucination” is used to describe such
cases, in contrast to those which are attributed to demonstrable
underlying pathology, i.e., symptomatic musical hallucinations.
The prevalence of musical hallucinations seems to be higher
than traditionally suspected, even when taking into account a
review by Cope and Baguley (3) who reported their presence in
almost 1% of individuals in a population with acquired hearing
loss. Experienced clinicians report relatively frequent encounters
with people experiencing them (4), and a survey among patients
referred for audiometric testing found musical hallucinations in
3.6% of the cases (5). The pathophysiology of such hallucina-
tions is probably diverse and certainly needs further elucidation.
A magnetoencephalography (MEG) study in one individual with
musical hallucinations and hearing loss indicates involvement of
right temporoparietal areas (6), whereas a more recent MEG study
in a similar patient indicates involvement of the left anterior supe-
rior temporal gyrus, motor cortex, posteromedial cortex, and left
lateral orbitofrontal cortex at the onset of hallucinations after a
residual inhibition paradigm (7). However, apart from those spe-
cific areas, the vast brain network involved in their mediation
seems to comprise auditory areas, basal ganglia, brainstem, pons,
tegmentum, cerebellum, hippocampi, amygdala, visual areas and,
in some cases, perhaps also the peripheral auditory system (4).
The risk factors for musical hallucinations are also complex and
diverse (Table 1).
The main risk factors for musical hallucinations are impaired
hearing, tinnitus, advanced age and, perhaps, also female sex; how-
ever, the latter finding may be due to an overrepresentation of
females in the literature (4). It remains uncertain whether psy-
chosis, schizotypal or schizoid personality, and other psychiatric
disorders increase the risk for musical hallucinations (8–11).
Evidence-based treatment protocols are lacking. However, case
reports and small case series indicate that some people can be
treated non-pharmacologically through psychoeducation, use of
a hearing aid, and/or attention-diverting activities, whereas others
can be treated pharmacologically with anticonvulsants, antide-
pressants, or antipsychotics; however, in many cases, the halluci-
nations prove refractory to treatment (4, 12). Here, we present
two patients who derived benefit from the acetylcholinesterase
inhibitor rivastigmine. Based on these two cases and a discussion
of similar earlier cases, we explore possible mechanisms of action
for acetylcholinesterase inhibitors in the treatment of musical
hallucinations.
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Table 1 | Known risk factors for musical hallucinations: after Sacks and
Blom (4).
Hearing impairment
Tinnitus
Older age
Female sex (possibly)
Cerebral pathology
Epilepsy
Brain tumor
Stroke
Hemorrhage
Meningitis
Neurodegenerative disease (Alzheimer’s disease, Lewy body dementia)
Neurosyphilis
Localized atrophy
Traumatic lesion
Psychiatric disorder
Schizophrenia spectrum disorder
Bipolar disorder
Psychotic depression
Depression
Obsessive–compulsive disorder
Adaptation impairment
Personality disorder
ADHD
Cocaine dependence
Intoxication
Alcohol
Antidepressants
Opioids
Antibiotics
Beta blockers
Quinine
Salicylates
Miscellaneous
Behçet’s disease
Hashimoto’s encephalopathy
Lyme disease
Electroconvulsive treatment
Cochlear implantation
Sensory deprivation
MATERIALS AND METHODS
We describe two patients, the first of whom is a 76-year-old
female who was treated at the outpatient clinic of Parnas-
sia Psychiatric Institute (The Hague, the Netherlands). As this
patient died at age 80 years, written consent to publish was
obtained from her son. The second patient is a 78-year-old
female who was treated at Ashford/St. Peter’s Hospital (Chert-
sey, UK). Due to her sudden death no consent to publish could
be obtained. For the present review, we conducted a systematic
search in Pubmed and the Ovid database, which included EMBASE
(1980 through November 2014), Ovid Medline (1948 through
November 2014), and PsycINFO (1806 through November 2014).
In each database, the search terms musical hallucination, musi-
cal hallucinosis, and auditory Charles Bonnet syndrome, were
used separately. Each of the terms was then combined sepa-
rately with cholinesterase inhibitor, acetylcholinesterase inhibitor,
rivastigmine, and donepezil.
RESULTS
CASE REPORTS
Patient 1
In 2009, a 76-year-old woman with impaired hearing was referred
because of musical hallucinations, which she had experienced
since her husband’s death 6 years earlier. On the day of his death,
she had suddenly heard hymns, lullabies, pop songs, and classi-
cal tunes, which repeated themselves indefinitely before changing
into different pieces of music. Although she perceived them inside
the head, they had a definite perceptual quality. They were present
from the moment she awoke until late at night, and she used a
radio to drown them out when trying to sleep. During the day-
time, they receded into the background only when she carried out
tasks that required her full attention. Because she and her husband
had shared a fondness for the same music, she initially consid-
ered the hallucinations to be a sign of ongoing interconnectedness
between the two of them. This conviction was strengthened by
various hypnagogic episodes during which she once saw her hus-
band surrounded by a bright light, and on other occasions felt
a presence nearby or a hand through her hair. After 6 months,
the musical hallucinations had exhausted her to such an extent
that she consulted a psychologist, who interpreted them as part of
a normal grieving process and offered her counseling – which
she quit after a few sessions. When she consulted our group
5 years later, she was not receiving any psychiatric treatment. Her
somatic history comprised tension headaches, asthma, arthritis,
and a myocardial infarction. Her medication consisted of acetyl-
salicylate, dipyridamole, pantoprazole, isosorbide mononitrate,
simvastatin, salbutamol, and tiotropium bromide. We found no
evidence for any of these medications to be a potential cause of her
hallucinations, except for the acetylsalicylate (13). The psychiatric
examination yielded no abnormalities other than the grief-related
hypnagogic phenomena described above. Notably, there were no
signs of other hallucinations, depression, psychosis, schizotypy, or
cognitive decline (although the latter was not formally tested). The
neurological examination and the electroencephalogram (EEG)
were also unremarkable. Magnetic resonance imaging (MRI) of
the brain showed multiple white-matter lesions, especially in the
right inferior frontal area and the left parietal lobe, but nothing
unusual for her age. To rule out the possibility that the hallucina-
tions were caused by the use of acetylsalicylate, the latter drug was
changed to clopidogrel, but without any effect. Despite the nega-
tive EEG findings, we then prescribed 150 mg of valproic acid; with
this treatment, the musical hallucinations diminished substantially
and our patient experienced a range of symptom-free hours every
day. We also advised her to use her hearing aid, to optimize the
use of her radio, and to engage in social events; however, these
latter activities had no effect. Meanwhile, because a higher dose
of valproic acid was not well tolerated, in an attempt to improve
her condition we tapered it off and proposed rivastigmine instead.
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As in dementia, we titrated the rivastigmine dose upwards; how-
ever, because our patient reported severe dizziness at a dosage of
4.5 mg, we advised her to reduce the dose to 1.5 mg/day. Within a
few days, the musical hallucinations had vanished completely. At
this low dose, there were no side-effects and, during a follow-up
period of 4 years until her death in 2013 due to a cerebral hemor-
rhage, she remained symptom-free, even though she occasionally
missed a dose of rivastigmine.
Patient 2
In 2014, a 78-year-old woman with hearing impairment was
referred because of musical hallucinations, which had been present
for 1 year. Initially, she was convinced that the people next door
kept playing Christmas carols, even at night and when they had
left the house. Later, the experienced music was unrecognizable to
her. She felt she wanted to harm the neighbors, and also became
estranged from her sister who maintained that she did not hear the
music. Despite also hearing it when she stayed at her daughter’s
home, she continued to believe that the neighbors were caus-
ing the noise. Adjusting the hearing aids that she had worn for
1 year brought no relief, but watching TV reduced the volume
of the hallucinated music. She scored the usual level of loud-
ness on a visual analog scale (VAS) as 8–9/10 and stated that
the noise interfered with her falling asleep. Our patient had lived
alone for 20 years and on most days did not speak to anyone.
Although there was no psychiatric history, due to the hallucina-
tions she developed a depressed mood, which did not improve
significantly with mirtazapine. Her other medications comprised
metformin, gliclazide, sitagliptin, co-codamol, simvastatin, and
atenolol, neither of which could be held responsible for her hallu-
cinations. There were no abnormalities on neurological and psy-
chiatric examination. Notably, we found no evidence for any other
types of hallucination. In the consulting room, the musical hal-
lucinations commenced after 30 s of silence. The Addenbrooke’s
Cognitive Examination-Revised (ACE-R) score was 79/100, sug-
gesting mild cognitive impairment (MCI). An MRI scan of the
brain showed unremarkable white-matter changes. Within days
of starting rivastigmine 1.5 mg, the music became less frequent
and less loud (VAS 5/10) and her anger and depressed mood dis-
appeared. We did not repeat ACE-R, but insight into the origin
of the music improved significantly even though at times she still
suspected the neighbors. Three months after starting the rivastig-
mine, in the consulting room the music started after 1 min, rather
than after 30 s, of silence. The dose was increased to 4.5 mg/day in
an attempt to treat both the hallucinations and MCI, but 6 months
later she died suddenly due to pneumonia.
LITERATURE SEARCH
Our search yielded 210 papers on musical hallucinations and
72,999 papers on acetylcholinesterase inhibitors. Of those papers,
three described four original cases involving the successful treat-
ment of musical hallucinations with the acetylcholinesterase
inhibitor donepezil (14–16). A fourth paper (6), which appar-
ently described one of those four cases (14) at an earlier stage, was
omitted. Table 2 provides a summary of the four original cases
plus a summary of our two present cases.
DISCUSSION
All six cases published so far are consistent with the definition of
idiopathic musical hallucinations, even though one of the patients
described by Strauss and Gertz (15) experienced an intensifica-
tion of preexisting musical hallucinations after a stroke. Regarding
their pathophysiology, such hallucinations are conceptualized as
deafferentiation phenomena, i.e., release hallucinations evoked by
the relative absence of normal auditory input (4, 14). As noted by
Ukai et al. (14), age-dependent dysfunction of cholinergic neurons
may be a predisposing condition for the mediation of such release
phenomena.
The brain’s cholinergic system is mainly involved not only in
attention, learning, and memory but also in visual perception and
visual attention (the latter being modulated by gamma oscillations
and possibly also by low-frequency alpha/beta oscillations under
the influence of ACh in visual cortex) (18). Thus, there is sub-
stantial evidence for the efficacy of acetylcholinesterase inhibitors
in the treatment of visual hallucinations experienced in the con-
text of Parkinson’s disease (19–21). In addition, there is evidence
for their efficacy in instances of isolated visual hallucinations.
For example, Ukai et al. (22) described a patient with isolated
visual hallucinations in the absence of cognitive decline who
was successfully treated with donepezil; also, our group reported
the successful treatment of visual disorders of perception with
rivastigmine (17).
Animal studies suggest that cortical cholinergic input is also
required for normal auditory perception (23). In humans, Iri-
majiri et al. (24) found that acetylcholinesterase inhibitors alter
auditory cortical somatosensory potentials (N20, P50) in treated
versus untreated MCI patients, while a study among Alzheimer
patients indicates that they also alter resting-state EEG rhythms
(25). Our knowledge of ACh in the perception, storage, produc-
tion, and reproduction of music is still in its infancy, even though
its involvement in auditory learning and memory has been estab-
lished in animal studies and implications for neuromusic research
are considered imminent (26). The role of ACh in the processing
of music is supported by case reports on potent anticholinergic
antidepressants (such as amitriptyline) and their ability to evoke
musical hallucinations (9, 27), and on studies of musical hallucina-
tions in association with degenerative brain diseases characterized
by cholinergic deficits, such as Alzheimer’s disease and Lewy body
disease (19, 28).
The receptor sites responsible for the mechanism of action
of acetylcholinesterase inhibitors in cases of musical hallucina-
tion are as yet unknown. Postsynaptically, ACh acts upon nico-
tinic and muscarinic acetylcholine receptors. Acetylcholinesterase
inhibitors increase the presynaptic availability, as well as the dura-
tion of action of ACh, by preventing the acetylcholinesterase
enzyme from breaking this neuromodulator down. Rivastig-
mine, a brain-selective “pseudo-irreversible” acetylcholinesterase
inhibitor, prevents the breakdown of ACh for a duration of 10 h
(29). Animal studies have shown that rivastigmine has a specific
effect on cortex and hippocampus (30). Because musical hallu-
cinations often present in the form of familiar songs and other
pieces remembered from the past (31), the hippocampus with its
central role in memory and emotion seems a likely candidate.
That hypothesis is further supported by the deactivation of the
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Table 2 | Overview of reported cases of musical hallucinations treated with acetylcholinesterase inhibitors.
Reference Patient Content of MHs Tinnitus Hearing
loss
Comorbid
disorders
Results of
auxiliary
investigations
Treatment Clinical
efficacy
Duration of
follow-up
Ukai et al.
(14)
F, 82 years Old familiar songs
accompanied by
musical instruments
which later evolved
into monotonous,
simple melodies
− + − MRI: diffuse mild
cortical atrophy
consistent with
aging
Donepezil
5 mg/day (plus
polypharmacy)
Almost
complete
remission
5 years
Strauss
and Gertz
(15)
M, 54 years Songs sung by a male
voice, sometimes
accompanied by piano
or guitar, and
sometimes orchestral
music
+ + Hemiparesis
due to
infarctions of
the bilateral
medial
cerebral
artery
territories
MRI: extensive
ischemic lesions
in the right medial
cerebral artery
territory, including
insular cortex and
basal ganglia, and
left occipital
ischemic lesions
Donepezil
5 mg/day
Complete
remission
8 weeks
Strauss
and Gertz
(15)
M, 78 years Christmas carols and
folk songs, sung by a
male voice
+ + − MRI: symmetric
diffuse brain
atrophy and
periventricular
microangiopathic
changes
Donepezil
5 mg/day
Complete
remission
4 months
Zilles
et al. (16)
F, 90 years Choirs and brass
music
− + Reactive
depression
MRI: global brain
atrophy, bifrontal
hygromas, and a
leukodystrophia-
like brain
parenchyma
Donepezil
5 mg/day
Complete
remission
1 week
Blom
et al. (17)
F, 76 years Hymns, lullabies, pop
songs, and classical
tunes
− + Myocardial
infarction
MRI:
white-matter
lesions, especially
in the right
inferior frontal
area and the left
parietal lobe
Rivastigmine
1.5 mg/day
(plus
polypharmacy)
Complete
remission
4 years
Blom
et al. (17)
F, 78 years Christmas carols and
(later) unrecognizable
music
− + − MRI:
white-matter
lesions,
non-specific
Rivastigmine
1.5 mg/day
(plus
polypharmacy)
Partial
remission
3 months
MHs, musical hallucinations; F, female; M, male.
hippocampus in functional MRI studies of verbal auditory hallu-
cinations (32). In addition, posterior medial cortex (with its role
in memory and perception) may be involved in the retrieval of
musical melody from memory (7). Other candidate mechanisms
include those found by Kumar et al. (7), i.e., an increase in the
gamma band in left anterior superior temporal gyrus with stronger
hallucinations (which is normally involved in melody perception),
in the beta band in motor cortex and posteromedial cortex, and in
the theta/alpha bands in left lateral orbitofrontal cortex (associated
with unpleasant music).
CONCLUSION AND LIMITATIONS
Although our knowledge of ACh and its role in the processing
of music needs further elucidation, there are reasons to con-
sider acetylcholinesterase inhibitors for pharmacoclinical research
in musical hallucinations associated with hearing loss. First of
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all, they seem to be safer and to yield fewer side-effects than
antipsychotics, antidepressants, and anticonvulsants (33). Second,
they may even yield beneficial side-effects when administered
to patients suffering from comorbid cognitive decline. Further-
more, a beneficial effect may be obtained relatively quickly. For
example, in the six patients described above, acetylcholinesterase
inhibitors were effective within a few days (i.e., much faster than
the antipsychotics used in patients experiencing verbal auditory
hallucinations), at a low dose (rivastigmine 1.5 mg is much lower
than the 9 mg dose used for dementia), and with substantial effect.
Nevertheless, most of the evidence for the involvement of ACh
in the mediation of musical hallucinations is indirect and based
on observations among very small numbers of patients. More-
over, there may be some publication bias as musical hallucinations
refractory to treatment with acetylcholinesterase inhibitors may
have remained unreported. For other types of musical halluci-
nation, especially those not associated with hearing loss and/or
deafferentiation, the efficacy of these drugs has not yet been
established.
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